Literature DB >> 1693055

Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions.

D P Healy1, J V Sahai, S H Fuller, R E Polk.   

Abstract

Vancomycin-induced "red man syndrome" (RMS) is mediated in part by histamine release, and its severity is correlated with the area under the plasma histamine concentration-time curve. Ten adult male volunteers participated in a randomized, double-blind, two-way crossover trial (1-week washout interval between regimens) to determine the effect of 1- and 2-h infusions of vancomycin (1.0 g) on histamine release and on the frequency and severity of RMS. The severity of RMS was classified a priori as mild, moderate, or severe from a combined score of pruritus and extent of erythema. Serial concentrations of histamine in plasma and concentrations of vancomycin in serum were measured at baseline and during and after each infusion. Of 10 subjects, 8 had evidence of RMS during the 1-h infusion (3 mild, 3 moderate, and 2 severe), whereas only 3 of the 10 subjects (all mild) had RMS during the 2-h infusion (P less than 0.05). The 1-h infusion was associated with a significantly greater peak concentration of histamine in plasma (1.8 +/- 0.7 versus 1.0 +/- 0.3 ng/ml, P = 0.004) and a greater total release of histamine (74.3 +/- 54.1 versus 36.4 +/- 22.6 ng.min/ml, P = 0.017) than was the 2-h infusion. These data suggest that administration of vancomycin over 2 h reduces the frequency and severity of RMS and the amount of histamine released compared with those after a 1-h infusion in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693055      PMCID: PMC171642          DOI: 10.1128/AAC.34.4.550

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome.

Authors:  J Sahai; D P Healy; R Garris; A Berry; R E Polk
Journal:  J Infect Dis       Date:  1989-11       Impact factor: 5.226

2.  Influence of bacterial endotoxins on basophil histamine release. Potentiation of antigen- and bacteria-induced histamine release.

Authors:  S Norn; L Baek; C Jensen; P S Skov; H Permin; J O Jarløv; C Koch
Journal:  Allergy       Date:  1986-02       Impact factor: 13.146

3.  Non-IgE-dependent bacteria-induced histamine release from human lung and tonsillar mast cells.

Authors:  M K Church; S Norn; G J Pao; S T Holgate
Journal:  Clin Allergy       Date:  1987-07

4.  Vancomycin and the red-man syndrome: pharmacodynamics of histamine release.

Authors:  R E Polk; D P Healy; L B Schwartz; D T Rock; M L Garson; K Roller
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

5.  Vancomycin and the "red man's syndrome".

Authors:  J C Garrelts; J D Peterie
Journal:  N Engl J Med       Date:  1985-01-24       Impact factor: 91.245

6.  Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers.

Authors:  M Boeckh; H Lode; K Borner; G Höffken; J Wagner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

7.  Histamine release by vancomycin: a mechanism for hypotension in man.

Authors:  J H Levy; N Kettlekamp; P Goertz; J Hermens; C A Hirshman
Journal:  Anesthesiology       Date:  1987-07       Impact factor: 7.892

8.  The histamine flare response in diabetes mellitus.

Authors:  K J Hutchison; B W Johnson; H T Williams; G D Brown
Journal:  Surg Gynecol Obstet       Date:  1974-10

9.  Staphylococcus aureus peptidoglycan induces histamine release from basophil human leukocytes in vitro.

Authors:  F Espersen; J O Jarløv; C Jensen; P S Skov; S Norn
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

10.  Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin.

Authors:  H Lagast; P Dodion; J Klastersky
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

View more
  24 in total

1.  Vancomycin-induced red man syndrome in pediatric oncology: still an issue?

Authors:  Tiene Bauters; Barbara Claus; Petra Schelstraete; Hugo Robays; Yves Benoit; Catharina Dhooge
Journal:  Int J Clin Pharm       Date:  2011-12-13

Review 2.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

3.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

4.  The study of vancomycin use and its adverse reactions associated to patients of a Brazilian university hospital.

Authors:  Daniel Savignon Marinho; Gisele Huf; Bruno L A Ferreira; Helena Castro; Carlos R Rodrigues; Valeria Pereira de Sousa; Lúcio M Cabral
Journal:  BMC Res Notes       Date:  2011-07-15

5.  Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.

Authors:  James M Kidd; Colleen M Sakon; Louise-Marie Oleksiuk; Jeffrey J Cies; Rebecca S Pettit; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

6.  Influence of vancomycin infusion methods on endothelial cell toxicity.

Authors:  Maryline Drouet; Feng Chai; Christine Barthélémy; Gilles Lebuffe; Bertrand Debaene; Bertrand Décaudin; Pascal Odou
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

7.  Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome".

Authors:  J Sahai; D P Healy; M J Shelton; J S Miller; S J Ruberg; R Polk
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 8.  An updated comparison of drug dosing methods. Part IV: Vancomycin.

Authors:  R D Pryka; K A Rodvold; S M Erdman
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 9.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

10.  Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin.

Authors:  M J Rybak; E M Bailey; L H Warbasse
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.